In this study, we analyzed the distribution of subtypes of EGFR exon 18 mutation and the clinical outcomes of advanced NSCLC patients with EGFR exon 18 mutations receiving different treatment strategies as first-line therapy. Here, EGFR is linked to non-small cell lung carcinoma.